NuVasive (NUVA) Expands Training Opportunities With New Center


NuVasive, Inc.


NUVA

recently announced the expansion of opportunities to train more surgeons and change more patient lives with the opening of its East Coast Experience Center in the New York metropolitan area. The East Coast Experience Center compliments NuVasive’s flagship experience center in San Diego headquarters.

The latest development is likely to expand NuVasive’s opportunities to advance the company’s market-leading surgeon training and education program.

NuVasive CPD Program

The NuVasive Clinical Professional Development (CPD) program is intended for the growth of surgeons through the design and delivery of advanced clinical education programs. The program includes competency-based courses led by dedicated surgeon faculty members which provide peer-to-peer training and opportunities to gain valuable insights from real-world scenarios.

More on NuVasive East Coast Experience Center

As part of the NuVasive’s CPD program, the East Coast Experience Center will be a leading destination for surgeon training and education in key global markets.

The East Coast Experience Center features educational training rooms with advanced cameras and streaming capabilities for effective learning virtually. The Center will have dedicated Pulse platform demonstration site to offer practical experience with the only enabling technology platform currently available in the market that has the ability for utilization in 100% of spine procedures.

Significance of the New Center Opening

Per NuVasive’s management, the East Coast Experience Center validates the company’s commitment to best quality surgeon education and training to help enhance the standard of patient care in spine surgery.

Zacks Investment Research
Image Source: Zacks Investment Research

The latest investment continues to play a vital role in the implementation of NuVasive’s spine procedures and technologies, especially with the integration of the Pulse platform into the procedural offering. Together with the surgeons, NuVasive is working to transform surgery, enhance patient care, and change more patient lives globally.

Recent Developments

In July 2021, NuVasive announced the receipt of the FDA 510(k) clearance for the Pulse platform – the first-of-its-kind platform which integrates multiple technologies to tackle most common clinical challenges in spine surgery. The company also announced the commercial launch of Pulse platform, which is now available for sale in targeted global regions.

In the same month, NuVasive announced the commercial launch of Modulus ALIF — a 3D-printed porous titanium implant for anterior lumbar interbody fusion (ALIF) in targeted global regions. Modulus ALIF is the newest addition to the NuVasive Advanced Materials Science (AMS) portfolio and offers implants and instrumentation intended for both supine ALIF and XALIF procedures.

Industry Prospects


Per a report by MARKETSANDMARKETS

, the global spinal implants and surgery devices market is expected to reach $13.8 billion by 2025 from $10.3 billion in 2019, at a CAGR of 5.0%. The advancement in spine surgery technologies, increasing incidence of spinal disorders, the launch of advanced bone grafting products, and the increasing adoption of minimally-invasive spine surgeries are the factors driving the market.

Price Performance

Shares of the company have gained 28.5% in a year’s time compared with the

industry

’s rise of 12.5%.

Zacks Rank and Key Picks

Currently, NuVasive carries a Zacks Rank #3 (Hold).

A few better-ranked stocks from the broader medical space are

Envista Holdings Corporation


NVST

,

BellRing Brands, Inc.


BRBR

and

Biolase, Inc.


BIOL

, each carrying a Zacks Rank #2 (Buy). You can see


the complete list of Zacks #1 Rank (Strong Buy) stocks here.

Envista Holdings has an estimated long-term earnings growth rate of 27%.

BellRing Brands has an estimated long-term earnings growth rate of 29%.

Biolase has a projected long-term earnings growth rate of 15%.


Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.


Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report


To read this article on Zacks.com click here.